4PTE image
Entry Detail
PDB ID:
4PTE
Title:
Structure of a carvoxamide compound (15) (N-[4-(ISOQUINOLIN-7-YL)PYRIDIN-2-YL]CYCLOPROPANECARBOXAMIDE) to GSK3b
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2014-03-10
Release Date:
2015-04-08
Method Details:
Experimental Method:
Resolution:
2.03 Å
R-Value Free:
0.19
R-Value Work:
0.16
R-Value Observed:
0.17
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Glycogen synthase kinase-3 beta
Chain IDs:A, B
Chain Length:441
Number of Molecules:2
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Discovery of new acylaminopyridines as GSK-3 inhibitors by a structure guided in-depth exploration of chemical space around a pyrrolopyridinone core.
Bioorg.Med.Chem.Lett. 25 1856 1863 (2015)
PMID: 25845281 DOI: 10.1016/j.bmcl.2015.03.046

Abstact

Glycogen synthase kinase-3 (GSK-3) has been proposed to play a crucial role in the pathogenesis of many diseases including cancer, stroke, bipolar disorders, diabetes and neurodegenerative diseases. GSK-3 inhibition has been a major area of pharmaceutical interest over the last two decades. A plethora of reports appeared recently on selective inhibitors and their co-crystal structures in GSK-3β. We identified several series of promising new GSK-3β inhibitors from a coherent design around a pyrrolopyridinone core structure. A systematic exploration of the chemical space around the central spacer led to potent single digit and sub-nanomolar GSK-3β inhibitors. When dosed orally in a transgenic mouse model of Alzheimer's disease (AD), an exemplary compound showed significant lowering of Tau phosphorylation at one of the GSK-3 phosphorylating sites, Ser396. X-ray crystallography greatly aided in validating the binding hypotheses.

Legend

Protein

Chemical

Disease

Primary Citation of related structures